Hemogenyx Pharmaceuticals plc announces that it has allotted 7,741,935 new ordinary shares of £0.01 each in the Company in settlement of an arrangement fee due to the arranger of the Financing Facility announced on 18 November 18 2020 and approved by the Company’s shareholders on 6 January 2021, under which an initial draw down of £12,000,000 was made on 3 February 2021.
February 10, 2021
· 2 min read